Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Nasal Inhalation of Tobramycin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization

This study has been completed.
Information provided by (Responsible Party):
PD Dr. Jochen G. Mainz, University of Jena Identifier:
First received: October 16, 2008
Last updated: December 3, 2014
Last verified: December 2014
The purpose of this study is to determine whether the nasal inhalation of Gernebcin® is effective to decrease the Pseudomonas aeruginosa bacterial count in the nasal lavage fluid.

Condition Intervention Phase
Cystic Fibrosis
Pseudomonas Aeruginosa
Drug: Tobramycin (Gernebcin®)
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Nasal Inhalation of Tobramycin by the Pari Sinus Nebulizer in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization in the Upper Airways

Resource links provided by NLM:

Further study details as provided by University of Jena:

Primary Outcome Measures:
  • Decrease of Pseudomonas aeruginosa bacterial count in the nasal lavage fluid [ Time Frame: day -1, 1, 29, 30, 59, 60 ]

Secondary Outcome Measures:
  • Measure of serum levels of tobramycin [ Time Frame: day 1, 30 and 60 ]
  • Tolerability [ Time Frame: day 1, 30 and 60 ]

Enrollment: 9
Study Start Date: October 2008
Study Completion Date: November 2010
Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Tobramycin 80 mg
applied once daily via Pari Sinus nebulizer
Drug: Tobramycin (Gernebcin®)
1 ml / day in each nostril
Placebo Comparator: isotonic saline
applied once daily via Pari Sinus nebulizer
Drug: Tobramycin (Gernebcin®)
1 ml / day in each nostril


Ages Eligible for Study:   8 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • subject has a confirmed diagnosis of cystic fibrosis
  • detection of P. aeruginosa in nasal lavage (culture) with chronic P.a. colonization of the lung (from day -28)
  • informed consent of the patients or parents
  • subject is older than 7 years
  • subject is able to comply with the inhalation procedures and nasal lavage procedures scheduled in the protocol
  • women of childbearing potential are only included into the study, if they are using an effective method of birth control during the protocol

Exclusion Criteria:

  • subject has a critical condition defined as: FEV1 < 30% and / or SaO2 < 93% without O2-substitution; need of O2-substitution
  • subject had an ENT surgery within 3 months prior to study
  • subject shows signs of nasal bleeding
  • subject has an ear drum perforation
  • subject had an acute rhinosinusitis or a pulmonary exacerbation at study entry with need of additional systemic antibiotic therapy against pseudomonas aerug.
  • subject is unlikely to comply with the procedures scheduled in the protocol
  • subject has a known allergic reaction to the medication
  • subject is pregnant or breastfeeding
  • subject participates in another clinical trial within 30 days prior to study entry or 30 days after end of the study.
  • systemic (oral or intravenous) antibiotic treatment against P.a. 14 days prior to the inclusion and during the study
  • if serum level of tobramycin is above 2 mg/l one hour after inhalation, subject has to withdraw the participation in the study.
  • progressed renal insufficiency
  • severe damage of the N. acusticus
  • dizziness (potential damage of. N. vestibularis)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00774072

Tübingen, Baden-Würtemberg, Germany, 72076
Mukoviszidosezentrum der Friedrich-Schiller-Universität
Jena, Thüringen, Germany, 07745
Sponsors and Collaborators
University of Jena
Study Chair: Jochen Mainz, M.D. University of Jena, Children`s hospital
  More Information

Responsible Party: PD Dr. Jochen G. Mainz, Head, CF Center, University of Jena Identifier: NCT00774072     History of Changes
Other Study ID Numbers: tobra nasal CF pilot
Study First Received: October 16, 2008
Last Updated: December 3, 2014

Keywords provided by University of Jena:
subjects with cystic fibrosis and pseudomonas aeruginosa colonization in the upper airways

Additional relevant MeSH terms:
Cystic Fibrosis
Pseudomonas Infections
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Gram-Negative Bacterial Infections
Bacterial Infections
Anti-Bacterial Agents
Anti-Infective Agents processed this record on May 22, 2017